Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Argus Pharmaceuticals |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00001998 |
To define the pharmacokinetic characteristics of Nystatin LF IV (intravenous) in human subjects with AIDS-related complex (ARC) after administration of a single IV dose at each of 4 dose levels.
Condition | Intervention |
---|---|
HIV Infections |
Drug: Nystatin |
Study Type: | Interventional |
Study Design: | Treatment, Dose Comparison, Pharmacokinetics Study |
Official Title: | Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have the following:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 72 hours of study entry:
Prior Treatment:
Excluded within 72 hours prior to study entry:
Active alcohol or drug abuse unless they have been off drugs and/or alcohol for two weeks prior to start of study.
Study ID Numbers: | 103A, AR-90-01-002 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00001998 |
Health Authority: | United States: Food and Drug Administration |
Nystatin Acquired Immunodeficiency Syndrome AIDS-Related Complex |
Virus Diseases Sexually Transmitted Diseases, Viral Clotrimazole HIV Infections Miconazole Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Tioconazole Nystatin AIDS-Related Complex Retroviridae Infections Immunologic Deficiency Syndromes |
Anti-Infective Agents RNA Virus Infections Slow Virus Diseases Disease Molecular Mechanisms of Pharmacological Action Immune System Diseases Infection Pharmacologic Actions |
Membrane Transport Modulators Anti-Bacterial Agents Pathologic Processes Syndrome Antifungal Agents Therapeutic Uses Lentivirus Infections Ionophores |